Skip to main content
SpringerLink
Log in

The Safety of HMG-CoA Reductase Inhibitors in Special Populations at High Cardiovascular Risk

  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Abstract

Controlled clinical studies and clinical experience over many years have proven that virtually all patients benefit from lipid-lowering therapy with statins, even those with normal LDL cholesterol levels. Several recent large outcome trials have further demonstrated the clinical benefits and safety of statins in patients with a wide-range of high risks for cardiovascular disease. Those patients at highest absolute cardiovascular risk generally have the most to gain from statin therapy. A variety of statins are available to lower plasma lipids to guideline levels, but all differ in their pharmacokinetic properties, drug interaction profiles, and risk of myotoxicity. This has been highlighted by the withdrawal of cerivastatin from the market as a result of serious safety concerns. This review examines the safety and effectiveness of statins in special populations at high risk of cardiovascular disease—patients with coronary heart disease, dyslipidaemia, diabetes, hypertension, nephrotic disease, HIV, organ transplant patients and the elderly—with a focus on clinically relevant differences in the properties of individual statins that may influence the risk of drug interactions and side effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 1994; 344: 1383-1389.

    Google Scholar 

  2. Shepherd J,Cobbe SM,Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med1995; 333: 1301-1307.

    Google Scholar 

  3. Sacks FM,Pfeffer MA,Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001-1009.

    Google Scholar 

  4. Serruys PWJC,de Feyter P,Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention. A randomized controlled trial. JAMA 2002; 287: 3215-3222.

    Google Scholar 

  5. Herd JA,Ballantyne CM,Farmer JA, et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol 1997; 80: 278-286.

    Google Scholar 

  6. Downs JR,Clearfield M,Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of the AFCAPS/ TexCAPS. JAMA 1998; 279: 1615-1622.

    Google Scholar 

  7. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-1357.

    Google Scholar 

  8. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: A randomised placebocontrolled trial. Lancet 2002; 360: 7-22.

    Google Scholar 

  9. Shepherd J,Blauw GJ,Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet 2002; 360: 1623-1630.

    Google Scholar 

  10. Sever PS,Dahlof B,Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac OutcomesTrial-Lipid LoweringArm(ASCOT-LLA):Amulticentre randomised controlled trial. Lancet 2003; 361: 1149-1158.

    Google Scholar 

  11. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs. usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002; 288: 2998-3007.

  12. Pasternak RC. The ALLHAT lipid lowering trial-less is less. JAMA 2002; 288: 3042-3044.

    Google Scholar 

  13. Stein EA. Managing dyslipidemia in the high-risk patient. Am J Cardiol 2002; 89(Suppl): 50C-57C.

    Google Scholar 

  14. Hsu I,Spinler SA,Johnson NE. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Ann Pharmacother 1995; 29: 743-759.

    Google Scholar 

  15. Mahley RW,Bersot TP. Drug therapy for hypercholesterolemia and dyslipidemia. In: Goodman and Gilman: The Pharmacological Basis of Therapeutics, 10th ed. NewYork: McGraw Hill, Medical Publishing Division, 2001: 971-1002.

    Google Scholar 

  16. Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 1988; 319: 24-33.

    Google Scholar 

  17. Tolman KG. The liver and lovastatin. Am J Cardiol 2002; 89: 1374-1380.

    Google Scholar 

  18. Dujovne CA. Side effects of statins: Hepatitis versus “Transaminitis”-Myositis Versus "CPKitis". Am J Cardiol 2002; 89: 1411-1413.

    Google Scholar 

  19. Ballantyne CM,Corsini A, Davidson MH, et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 2003; 163: 553-564.

    Google Scholar 

  20. Homberg JC,Abuaf N,Helmy-Khalil S, et al. Drug-induced hepatitis associated with anticytoplasmic organelle autoantibodies. Hepatology 1985; 5: 722-727.

    Google Scholar 

  21. Ballare M,Campanini M,Catania E,Bordin G,Zaccala G,Monteverde A. Acute cholestatic hepatitis during simvastatin administration. Recent Prog Med 1991; 82: 233-235.

    Google Scholar 

  22. Hartleb M,Rymarczyk G,Januszewski K. Acute cholestatic hepatitis associated with pravastatin. Am J Gastroenterol 1999; 94: 1388-1390.

    Google Scholar 

  23. Hartleb M,Biernat L,Kochel A. Drug-induced liver damage-A three-year study of patients from one gastroenterological department. Med Sci Monit 2002; 8: CR292-CR296.

    Google Scholar 

  24. McKenney JM,Proctor JD,Harris S,Chinchilli VM. A comparison of the efficacy and toxic effects of sustained vs. immediate-release niacin in hypercholesterolemic patients. JAMA 1994; 271: 672-677.

    Google Scholar 

  25. Pierce LR.Wysowski DK,Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990; 264: 71-75.

    Google Scholar 

  26. Omar MA,Wilson JP,Cox TS. Rhabdomyolysis and HMGCoA reductase inhibitors. Ann Pharmacother 2001; 35: 1096-1107.

    Google Scholar 

  27. Farmer JA,Torre-Amione G. Comparative tolerability of the HMG-CoAreductase inhibitors. Drug Saf 2000; 108: 351-352.

    Google Scholar 

  28. Hamilton-Craig I. Statin-associated myopathy. MJA 2001; 175: 486-489.

    Google Scholar 

  29. Omar MA,Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother 2002; 36: 288-295.

    Google Scholar 

  30. Bottorff M,Hansten P. Long-term safety of hepatic hydroxymethylglutaryl coenzyme A reductase inhibitors. Arch Intern Med 2000; 160: 2273-2280.

    Google Scholar 

  31. Igel M,Sudhop T,von Bergmann K. Metabolism and drug interactions of 3-hydroxy-3-methylglutarly coenzyme A-reductase inhibitors (statins). Eur J Clin Pharmacol 2001; 57: 357-364.

    Google Scholar 

  32. van Pujjenbroek EP,Du Buf-Vereijken PWG,Spooren PFMJ,van Doormaal JJ. Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gem-fibrozil. J Intern Med 1996; 240: 403-404.

    Google Scholar 

  33. Tobert JA. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol 1988; 62: 28J-34J.

    Google Scholar 

  34. Garnett WR. Interactions with hydroxymethylglutarylcoenzyme A reductase inhibitors. Am J Health Syst Pharm 1995; 52: 1639-1645.

    Google Scholar 

  35. Spach DH,Bauwens JE,Clark CD,Burke WG. Rhabdomyolysis associated with lovastatin and erythromycin use. West J Med 1991; 154: 213-215.

    Google Scholar 

  36. Lees RS,Lees AM. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. N Engl J Med 1995; 333: 664-665.

    Google Scholar 

  37. Meier C,Stey C,Brack T, et al. Rhabdomyolysis in patients treated with simvastatin and cyclosporin: Role of the hepatic P450 enzyme. Schweiz Med Wochenschr 1995; 125: 27-28.

    Google Scholar 

  38. Thompson PD,Clarkson P,Karas RH. Statin-associated myopathy. JAMA 2003; 289: 1681-1690.

    Google Scholar 

  39. Bays HE,Dujovne CA. Drug interactions of lipid-altering drugs. Drug Safety 1998; 19: 355-371.

    Google Scholar 

  40. Christians U,Jacobsen W, Floren LC. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: Are the statins mechanistically similar? Pharmacol Ther 1998; 80: 1-34.

    Google Scholar 

  41. Corsini A,Bellosta S,Baetta R, et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999; 84: 413-428.

    Google Scholar 

  42. Shek A,Ferrill MJ. Statin-fibrate combination therapy. Ann Pharmacother 2001; 35: 908-917.

    Google Scholar 

  43. Kitazawa E,Tamura N,Iwabuchi H, et al. Biotransformation of pravastatin sodium (I). Mechanisms of enzymatic transformation and epimerization of an allylic hydroxy group of pravastatin sodium. Biochem Biophys Res Commun 1993; 192: 597-602.

    Google Scholar 

  44. Fischer V,Johanson L,Heitz F, et al. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: Effect on human cytochrome P-450 and implications for metabolic drug interactions. Drug Metab Pharmacokinet 1999; 27: 410-416.

    Google Scholar 

  45. Corsini A,Maggi FM,Catapano AL. Pharmacology of competitive inhibitors of HMG-CoA reductase. Pharmacol Res 1995; 31: 9-27.

    Google Scholar 

  46. Wrighton SA,VandenBranden M,Ring BJ. The human drug metabolizing cytochromes P450. J Pharmacokinet Biopharm 1996; 24: 461-473.

    Google Scholar 

  47. Bertz RJ,Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997; 32: 210-258.

    Google Scholar 

  48. Thummel KE,Wilkinson GR. In vitro and in vivo drug interaction involving human CYP3A. Annu Rev Pharmacol Toxicol 1998; 38: 389-430.

    Google Scholar 

  49. Penzak SR,Chuck SK,Stajich GV. Safety and efficacy of HMG-CoA reductase inhibitors for treatment of hyperlipidemia in patients with HIV infection. Pharmacotherapy 2000; 20: 1066-1071.

    Google Scholar 

  50. Kanathur N,Mathai MG,Byrd RP Jr, et al. Simvastatindiltiazem drug interaction resulting in rhabdomyolysis and hepatitis. Tenn Med 2001; 94: 339-341.

    Google Scholar 

  51. Lee AJ,Maddix DS. Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin. Ann Pharmacother 2001; 35: 26-31.

    Google Scholar 

  52. Gutierrez CA. Sildenafil-simvastatin interaction: Possible cause of rhabdomyolysis? Am Fam Physician 2001; 63: 636-637

    Google Scholar 

  53. Peces R,Pobes A. Rhabdomyolysis associated with concurrent use of simvastatin and diltiazem. Nephron 2001; 89: 117-118.

    Google Scholar 

  54. Cheng CH,Miller C,Lowe C,Pearson VE. Rhabdomyolysis due to probable interaction between simvastatin and ritonavir. Am J Health Syst Pharm 2002; 15: 728-730.

    Google Scholar 

  55. Argov Z. Drug-induced myopathies. Curr Opin Neurol 2000; 109: 261-262.

    Google Scholar 

  56. Transon C,Leemann T,Vogt N, et al. In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin. Clin Pharmacol Ther 1995; 58: 412-417.

    Google Scholar 

  57. Kantola T,Backman JT,Niemi M, et al. Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. Eur J Clin Pharmacol 2000; 56: 225-229.

    Google Scholar 

  58. Staffa JA,Chang J,Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002; 346: 539-540.

    Google Scholar 

  59. Benghozi R,Bortolini M,Jia Y, et al. Frequency of creatine kinase elevation during treatment with fluvastatin. Am J Cardiol 2002; 89: 231-233.

    Google Scholar 

  60. Yu DK. The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions. J Clin Pharmacol 1999; 39: 1203-1211.

    Google Scholar 

  61. Wacher VJ,Wu CY,Benet LZ. Overlapping substrate specificities and tissue distribution of P450 3A and pglycoprotein: Implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 1995; 13: 129-134.

    Google Scholar 

  62. Rendic S,DiCarlo FJ. Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 1997; 29:413-580.

    Google Scholar 

  63. Wang E,Casciano CN,Clement RP,Johnson WW. HMGCoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. Pharm Res 2001; 18: 800-806.

    Google Scholar 

  64. Bizzaro N,Bagolin E,Milani L, et al. Massive rhabdomyolysis and simvastatin. Clin Chem 1992; 38: 1504.

    Google Scholar 

  65. Boyd RA,Stern RH,Stewart BH, et al. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. J Clin Pharmacol 2000; 40: 91-98.

    Google Scholar 

  66. Smith HT, Jokubaitis LA, Troendle AJ, et al. Pharmacokinetics of fluvastatin and specific drug interactions. Am J Hypertens 1993; 6: 375S-382S.

    Google Scholar 

  67. Kantola T,Kivisto KT,Neuvonen PG. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 1998; 64: 177-182.

    Google Scholar 

  68. Phillips KA,Veenstra DL,Oren E, et al. Potential role of pharmacogenomics in reducing adverse drug reactions. JAMA 2001; 286: 2270-2279.

    Google Scholar 

  69. Roden DM,George AL Jr. The genetic basis of variability in drug responses. Nature Rev 2002; 1: 37-44.

    Google Scholar 

  70. Naoumova RP,Marais AD,Mountney J, et al. Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG CoA reductase inhibitors in familial hypercholesterolaemia. Atherosclerosis 1996; 119: 203-213.

    Google Scholar 

  71. Thompson GR,O'Neill F,Seed M. Why some patients respond poorly to statins and how this might be remedied. Eur Heart J 2002; 23: 200-206.

    Google Scholar 

  72. Thompson GR. Poor responders to statins:Apotential target for stanol esters. Eur Heart J Suppl 1991; 1(Suppl S): S114-S117.

    Google Scholar 

  73. Karayan L,Qiu S,Dufour R, et al. Response to HMG CoA reductase inhibitors in heterozygous familial hypercholesterolaemia due to the 10-kb deletion ('French Canadian Mutation') of the LDL receptor gene. Arterioscler Thromb 1994; 14: 1258-1263.

    Google Scholar 

  74. Ordovas JM,Mooser V. The APOE locus and the pharmacogenetics of lipid response. Curr Opin Lipidol 2002; 13:113-117.

    Google Scholar 

  75. Marian AJ,Safavi F,Ferlic L, et al. Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin: The lipoprotein and coronary atherosclerosis study. J Am Coll Cardiol 2000; 35: 89-95.

    Google Scholar 

  76. Bray PF,Cannon CP,Goldschmidt-Clermont P, et al. The platelet Pl(A2) and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction. Am J Cardiol 2001; 88:347-352.

  77. Leitersdorf E,Eisenberg S,Eliav O, et al. Genetic determinants of responsiveness to the HMG-CoA reductase inhibitor fluvastatin in patients with molecularly de-fined heterozygous familial hypercholesterolemia. Circulation 1993; 87(Suppl III): III-35-III-44.

    Google Scholar 

  78. Lutucuta S,Ballantyne CM,Elghannam H, et al. Novel polymorphisms in promoter region of ATP binding cassette transporter gene and plasma lipids, severity, progression, and regression of coronary atherosclerosis and response to therapy. Circ Res 2001; 88: 969-973.

    Google Scholar 

  79. Mulder AB,van Lijf HJ,Bon MAM, et al. Association of polymorphism in the cytochrome CYP2D6 and the effi-cacy and tolerability of simvastatin. Clin Pharmacol Ther 2001; 70: 546-551.

    Google Scholar 

  80. Nordin C,Dahl ML,Eriksson M,Sjoberg S. Is the cholesterol-lowering effect of simvastatin influenced by CYP2D6 polymorphism? Lancet 1997; 1350: 29-30.

    Google Scholar 

  81. Herman RJ. Drug interactions and the statins. CMAJ 1999; 161: 1281-1286.

    Google Scholar 

  82. LaRosa JC,He J,Vupputuri S. Effect of statins on risk of coronary disease. A meta-analysis of randomized controlled trials. JAMA 1999; 282: 2340-2346.

    Google Scholar 

  83. The MRC/BHF Heart Protection Study. Press Release, November 2001. Available at: http://www.ctsu.ox.ac.uk/~hps/pr.shtml

  84. Jacobson TA,Schein JR,Williamson A,Ballantyne CM, Maximizing the cost-effectiveness of lipid-lowering therapy. Arch Intern Med 1998; 158: 1977-1989.

    Google Scholar 

  85. Second Joint Task Force. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J 1998; 19: 1434-1503.

    Google Scholar 

  86. American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care 2000; 23(Suppl 1): S57-S60.

    Google Scholar 

  87. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (AdultTreatment Panel III). JAMA 2001; 285: 2486-2497.

    Google Scholar 

  88. Jukema JW,Bruschke AV,van Boven AJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995; 91: 2528-2540.

    Google Scholar 

  89. Crouse J 3rd,Byington RP,Bond MG, et al. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLACII). Am J Cardiol 1995; 75: 455-459.

    Google Scholar 

  90. Waters D,Higginson L,Gladstone P, et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994; 89: 959-968.

    Google Scholar 

  91. Effect of simvastatin on coronary atheroma: The Multicentre Anti-Atheroma Study (MAAS). Lancet 1994; 344: 633-638.

  92. Blankenhorn DH,Azen SP,Kramsch DM, et al. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). The MARS Research Group. Ann Intern Med 1993; 119: 969-976.

    Google Scholar 

  93. Gotto AM Jr,Farmer JA. Pleiotropic effects of statins: Do they matter? Curr Opin Lipidol 2001; 12: 391-394.

    Google Scholar 

  94. Soma MR,Donetti E,Parolini C, et al. HMG CoA reductase inhibitors. In vivo effects on carotid intimal thickening in normocholesterolemic rabbits. Arterioscler Thromb 1993; 13: 571-578.

    Google Scholar 

  95. Igarashi M,Takeda Y,Mori S, et al. Suppression of neointimal thickening by a newly developed HMG-CoA reductase inhibitor, BAYw6228, and its inhibitory effect on vascular smooth muscle cell growth. Br J Pharmacol 1997; 120: 1172-1178.

    Google Scholar 

  96. Gellman J,Ezekowitz MD,Sarembock IJ, et al. Effect of lovastatin on intimal hyperplasia after balloon angioplasty: A study in an atherosclerotic hypercholesterolemic rabbit. J Am Coll Cardiol 1991; 17: 251-259.

    Google Scholar 

  97. Bocan TM,Mazur MJ,Mueller SB, et al. Antiatherosclerotic activity of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase in cholesterol-fed rabbits: A biochemical and morphological evaluation. Atherosclerosis 1994; 111: 127-142.

    Google Scholar 

  98. Bandoh T,Mitani H,Niihashi M, et al. Inhibitory effect of fluvastatin at doses insufficient to lower serum lipids on the catheter-induced thickening of intima in rabbit femoral artery. Eur J Pharmacol 1996; 315: 37-42.

    Google Scholar 

  99. Bevilacqua M,Bettica P,Milani M, et al. Effect of fluvastatin on lipids and fibrinolysis in coronary artery disease. Am J Cardiol 1997; 79: 84-87.

    Google Scholar 

  100. White CM. Pharmacological effects of HMG CoA reductase inhibitors other than lipoprotein modulation. J Clin Pharmacol 1999; 39: 111-118.

    Google Scholar 

  101. Eichstädt HW,Eskötter H,Hoffmann I, et al. Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease. Am J Cardiol 1995; 76: 122A-125A.

    Google Scholar 

  102. Mostaza JM,Gomez MV,Gallardo F, et al. Cholesterol reduction improves myocardial perfusion abnormalities in patients with coronary artery disease and average cholesterol levels. J Am Coll Cardiol 2000; 35: 76-82.

    Google Scholar 

  103. Hosokawa R,Nohara R,Linxue L, et al. Effect of long-term cholesterol-lowering treatment with HMG-CoA reductase inhibitor (simvastatin) on myocardial perfusion evaluated by thallium-201 single photon emission computed tomography. Jpn Circ J 2000; 64: 177-182.

    Google Scholar 

  104. Aengevaeren WR. Beyond lipids-The role of the endothelium in coronary artery disease. Atherosclerosis 1999; 147(Supp l): S11-S16.

    Google Scholar 

  105. Azie NE,Brater DC,Becker PA, et al. The interaction of diltiazem with lovastatin and pravastatin. Clin Pharmacol Ther 1998; 64: 369-377.

    Google Scholar 

  106. Gruer PJK,Vega JM,Mercuri MF, et al. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. Am J Cardiol 1999; 84: 811-815.

    Google Scholar 

  107. Mousa O,Brater DC,Sunblad KJ,Hall SD. The interaction of diltiazem with simvastatin. Clin Pharmacol Ther 2000; 67: 267-274.

    Google Scholar 

  108. Ahmad S. Diltiazem myopathy [letter]. Am Heart J 1993; 126: 1494-1495.

    Google Scholar 

  109. Ernst ME,Kelly MW. Mibefradil, a pharmacologically distinct calcium antagonist. Pharmacotherapy 1998; 18: 463-485.

    Google Scholar 

  110. Schmassmann-Suhijar D,Bullingham R,Gasser R, et al. Rhabdomyolysis due to interaction of simvastatin with mibefradil. Lancet 1998; 351: 1929-1930.

    Google Scholar 

  111. Paoletti R,Corsini A,Bellosta S. Pharmacological interactions of statins. Atheroscler Suppl 2002; 3: 35-40.

    Google Scholar 

  112. Stamler J,Daviglus ML,Garside DG, et al. Relationship between baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular and all cause mortality and longevity. JAMA 2000; 284: 311-318.

    Google Scholar 

  113. Vogel RA. Coronary risk factors, endothelial function and atherosclerosis: A review. Clin Cardiol 1997; 54: 1-8.

    Google Scholar 

  114. Pekkanen J,Linn S,Heiss G, et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990; 322: 700-707.

    Google Scholar 

  115. Gordon DJ,Probstfield JL,Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease: Four prospective American studies. Circulation 1989; 79: 8-15.

    Google Scholar 

  116. Watts GF. Treating patients with low high-density lipoprotein cholesterol: Choices, issues and opportunities. Curr Control Trials Cardiovasc Med 2001; 2: 118-122.

    Google Scholar 

  117. Kannel WB. Range of serum cholesterol values in the population developing coronary artery disease. Am J Cardiol 1995; 76: 69C-77C.

    Google Scholar 

  118. NIH Consensus Development Panel on Triglyceride, Highdensity Lipoprotein, and Coronary Heart Disease. NIH consensus conference: Triglyceride, high-density lipoprotein, and coronary heart disease. JAMA 1993; 269: 505-510.

    Google Scholar 

  119. Zambon A,Hokanson JE. Lipoprotein classes and coronary disease regression. Curr Opin Lipidol 1998; 9: 329-336.

    Google Scholar 

  120. Austin MA,Hokanson JE,Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998; 81: 7B-12B.

    Google Scholar 

  121. Kuhn FE,Mohler ER,Satler LF, et al. Effects of highdensity lipoprotein on acetylcholine-induced coronary vasoreactivity. Am J Cardiol 1991; 68: 1425-1430.

    Google Scholar 

  122. Mackness MI,Abbott C,Arrol S,Durrington PN. The role of high-density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem J 1993; 294: 829-834.

    Google Scholar 

  123. Durrington PN,Mackness B,Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21: 473-480.

    Google Scholar 

  124. Ballantyne CM,Herd JA,Ferlic LL, et al. Influence of low HDLon progression of coronary artery disease and response to fluvastatin therapy. Circulation 1999; 99: 736-743.

    Google Scholar 

  125. Ballantyne CM,Olsson AG,Cook TJ,Mercuri MF,Pedersen TR,Kjekshus J. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001; 104: 3046-3051.

    Google Scholar 

  126. Branchi A,Fiorenza AM,Torri A, et al. Atorvastatin increases HDL cholesterol in hypercholesterolemic patients. Evidence of a relationship with baseline HDL cholesterol. Nutr Metab Cardiovasc Dis 2002; 12: 24-28.

    Google Scholar 

  127. Narita Y,Kitazoe Y,Kurihara Y, et al. Increase or decrease of HDL-cholesterol concentrations during pravastatin treatment depending on the pre-treatment HDL cholesterol levels. Eur J Clin Pharmacol 1997; 52: 461-463.

    Google Scholar 

  128. Asztalos BF,Horvath KV,McNamara JR,Roheim PS,Rubinstein JJ,Schaefer EJ. Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients. Atherosclerosis 2002; 164: 361-369.

    Google Scholar 

  129. Mikhailidis DP,Wierzbicki AS. HDL-cholesterol and the treatment of coronary heart disease: Contrasting effects of atorvastatin and simvastatin. Curr Med Res Opin 2000; 16: 139-146.

    Google Scholar 

  130. Richter WO,Jacob BG,Schwandt P. Comparative effects of two HMG-CoA reductase inhibitors (lovastatin and pravastatin) on serum lipids and lipoproteins. Int J Tissue React 1991; 13: 107-110.

    Google Scholar 

  131. Ballantyne CM,Pazzucconi F,Pintó X, et al. Efficacy and tolerability of fluvastatin extended-release delivery system: A pooled analysis. Clin Ther 2001; 23: 177-192.

    Google Scholar 

  132. Stein EA,Lane M,Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am J Cardiol 1998; 81(4A): 66B-69B.

    Google Scholar 

  133. Branchi A,Fiorenza AM,Rovellini A, et al. Lowering effects of four different statins on serum triglyceride level. Eur J Clin Pharmacol 1999; 55: 499-502.

    Google Scholar 

  134. Cullen P. Evidence that triglycerides are an independent coronary heart disease risk factor. Am J Cardiol 2000; 86: 943-949.

    Google Scholar 

  135. Moriguchi EH,Vieira JL,Itakura H. Differences in the effects of fluvastatin on lipoprotein subclass distribution is dependent on triglyceride levels. Atheroscler Suppl 2001; 140: P 372 (Abstract).

    Google Scholar 

  136. Sacks FM,Tonkin AM,Craven T, et al. Coronary heart disease in patients with low LDL-cholesterol: Benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation 2002; 105: 1424-1428.

    Google Scholar 

  137. Sbarouni E,Kyriakides ZS,Kremastinos D. The effect of hormone replacement therapy alone and in combination with simvastatin on plasma lipids of hypercholesterolemic postmenopausal women with coronary artery disease. JAmColl Cardiol 1998; 32: 1244-1250.

    Google Scholar 

  138. Lemay A,Dodin S,Turcot L,Dechene F,Forest JC. Estrogen/progesterone replacement versus pravastatin and their sequential association in hypercholesterolemic postmenopausal women. Maturitas 2001; 40: 247-257.

    Google Scholar 

  139. Herrington DM,Werbel BL,Riley WA,Pusser BE,Morgan TM. Individual and combined effects of estrogen/progestin therapy and lovastatin on lipids and flow-mediated vasodilation in postmenopausalwomenwith coronary artery disease. J Am Coll Cardiol 1999; 33: 2030-2037.

    Google Scholar 

  140. Marz W,Scharnagl H,Abletshauser C, et al. Fluvastatin lowers atherogenic dense low-density lipoproteins in postmenopausal women with the atherogenic lipoprotein phenotype. Circulation 2001; 103: 1942-1948.

    Google Scholar 

  141. Herrington DM,Vittinghoff E,Lin F, et al. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS). Circulation 2002; 105: 2962-2967.

    Google Scholar 

  142. Gagne C,Bays HE,Weiss SR, et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002; 90: 1084-1091.

    Google Scholar 

  143. Shepherd J. Fibrates and statins in the treatment of hyperlipidaemia: An appraisal of their efficacy and safety. Eur Heart J 1995; 16: 5-13.

    Google Scholar 

  144. Guyton JR,Dujovne CA,Illingworth DR. Dual hepatic metabolism of cerivastatin-clarifications (letter). Am J Cardiol 1999; 84: 497.

    Google Scholar 

  145. Prueksaritanont T,Zhao JJ,Bennett MA, et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 2002; 301: 1042-1051.

    Google Scholar 

  146. Spence JD,Munoz CE,Hendricks L, et al. Pharmacokinetics of the combination of fluvastatin and gemfibrozil. Am J Cardiol 1995; 76: 80A-83A.

    Google Scholar 

  147. Knoll RW,Ciafone R,Galen M. Rhabdomyolysis and renal failure secondary to combination therapy of hyperlipidemia with lovastatin and gemfibozil. Conn Med 1993; 57: 593-594.

    Google Scholar 

  148. Tal A,Rajeshawari M,Isley W. Rhabdomyolysis associated with simvastatin-gemfibrozil therapy. South Med J 1997; 90: 546-547.

    Google Scholar 

  149. Duell PB,Connor WE,Illingworth DR. Rhabdomyolysis after taking atorvastatin with gemfibrozil. Am J Cardiol 1998; 81: 368-369.

    Google Scholar 

  150. Pauciullo P,Borgnino C,Paoletti R, et al. Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia. Atherosclerosis 2000; 150: 429-436.

    Google Scholar 

  151. Gavish D,Leibovitz E,Shapira I,Rubinstein A. Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: Efficacy and safety. J Intern Med 2000; 247: 563-569.

    Google Scholar 

  152. Farnier M,Bortolini M,Salko T, et al. Frequency of creatine kinase elevation during treatment with fluvastatin in combination with fibrates. Am J Cardiol 2003; 91: 238-240.

    Google Scholar 

  153. Brown G,Albers JJ,Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323: 1289-1298.

    Google Scholar 

  154. Jacobson TA,Chin MM,Fromell GJ, et al. Fluvastatin with and without niacin for hypercholesterolemia. Am J Cardiol 1994; 74: 149-154.

    Google Scholar 

  155. Jacobson TA,Amorosa LF. Combination therapy with fluvastatin and niacin in hypercholesterolemia: A preliminary report on safety. Am J Cardiol 1994; 26; 73: 25D-29D.

    Google Scholar 

  156. Hoogerbrugge N. Effects of atorvastatin on serum lipids of patients with familial hypercholesterolaemia. J Intern Med 1998; 244: 143-147.

    Google Scholar 

  157. Levy D,Larson MG,Vasan RS,Kannel WB,Ho KK. The progression from hypertension to congestive heart failure. JAMA 1996; 275: 1557-1562.

    Google Scholar 

  158. D'Agostino RB,Kannel WB,Stepanians MN,D'Agostino LC. Efficacy and tolerability of lovastatin in hypercholesterolemia in patients with systemic hypertension. AmJ Cardiol 1993; 71: 82-87.

    Google Scholar 

  159. Peters TK,Mehra M,Muratti EN. Efficacy and safety of fluvastatin in hypertensive patients. An analysis of a clinical trial database. Am J Hypertens 1993; 6: 340S-345S.

    Google Scholar 

  160. Tonolo G,Melis MG,Formato M, et al. Additive effects of Simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest 2000; 30: 980-987.

    Google Scholar 

  161. Sacks FM,Tonkin AM,Shepherd J, et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: The Prospective Pravastatin Pooling Project. Circulation 2000; 102: 1893-1900.

    Google Scholar 

  162. Athyros VG,Papageorgiou AA,Mercouris BR, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. TheGREekAtorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 2002; 18: 220-228.

    Google Scholar 

  163. Sposito AC,Mansur AP,Coelho OR,Nicolau JC,Ramires JA. Additional reduction in blood pressure after cholesterollowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril). Am J Cardiol 1999; 83: 1497-9, A8.

    Google Scholar 

  164. Borghi C,Prandin MG,Costa FV, et al. Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol 2000; 35: 549-555.

    Google Scholar 

  165. Kagansky N,Levy S,Berner Y, et al. Cholesterol lowering in the older population: Time for reassessment? QJM 2001; 94: 457-463.

    Google Scholar 

  166. Stein EA. Safety and efficacy of fluvastatin 80 mg/day in elderly hypercholesterolaemic patients. Poster presentation at the 73rd Scientific Sessions of the American Heart Association, 12-15 Nov. 2000, New Orleans Louisiana, USA.

  167. Davidson MH. Treatment of the elderly with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors: Focus on drug interactions. J Cardiovasc Pharmacol Therapeut 2001; 6: 219-229.

    Google Scholar 

  168. Lemaitre RN,Furberg CD,Newman AB, et al. Time trends in the use of cholesterol-lowering agents in older adults: The Cardiovascular Health Study. Arch Intern Med 1998; 158: 1761-1768.

    Google Scholar 

  169. Sica DA,Gehr TWB. Rhabdomyolysis and statin therapy: Relevance to the elderly. Am J Geriatr Cardiol 2002; 11: 48-55.

    Google Scholar 

  170. The MRC/BHF Heart Protection Study: Preliminary results. Conference Report. Int J Clin Pract 2002; 56: 53-56.

  171. Bruckert E,Liévre M,Giral P, et al. Efficacy and safety of fluvastatin XL in a large cohort of elderly patients. Am J Geriatr Cardiol 2003; 12: 225-231.

    Google Scholar 

  172. Castano G,Mas R,Fernandez L,Illnait J,Mesa M,Alvarez E,Lezcay M. Comparison of the Efficacy and Tolerability of Policosanol with Atorvastatin in Elderly Patients with Type II Hypercholesterolaemia. Drugs Aging 2003; 20: 153-163.

    Google Scholar 

  173. Wang PS,Solomon DH,Mogun H,Avorn J. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA 2000; 283: 3211-3216.

    Google Scholar 

  174. Chan P,Huang TY,Tomlinson B,Lee C,Lee YS. Shortterm safety and efficacy of low-dose simvastatin in elderly patients with hypertensive hypercholesterolemia and fasting hyperinsulinemia. J Clin Pharmacol 1997; 37: 496-501.

    Google Scholar 

  175. Jackevicius CA,Mamdani M,Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002; 288: 462-467.

    Google Scholar 

  176. Stamler J,Vaccaro O,Neaton JD,Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor InterventionTrial. Diabetes Care 1993; 16: 434-444.

    Google Scholar 

  177. Turner R,Cull C,Holman R. United Kingdom Prospective Diabetes Study 17: A 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med 1996; 124(1 Pt 2): 136-145.

    Google Scholar 

  178. Chiquette E,Chilton R. Cardiovascular disease: Much more aggressive in patients with type 2 diabetes. Curr Atheroscler Rep 2002; 4: 134-142.

    Google Scholar 

  179. Reaven GM,Chen Y-DI,Jeppesen J, et al. Insulin resistance and hyperinsulinemia in individuals with small, dense, low density lipoprotein particles. J Clin Invest 1993; 92: 141-146.

    Google Scholar 

  180. Austin MA,Edwards KL. Small, dense low density lipoprotein, and insulin resistance syndrome and noninsulindependent diabetes. Curr Opin Lipidol 1996; 7: 167-171.

    Google Scholar 

  181. Winkler K,Abletshauser C,Hoffmann MM, et al. Effect of fluvastatin slow-release on low-density lipoprotein (LDL) subfractions in patients with type 2 diabetes mellitus: Baseline LDL profile determines specific mode of action. J Clin Endocrinol Metab 2002; 87: 5485-5490.

    Google Scholar 

  182. Pontrelli L,Parris W,Adeli K,Cheung RC. Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/ type 2 diabetes. Metabolism 2002; 51: 334-342.

    Google Scholar 

  183. Tan KCB,Janus ED,Lam KSL. Effects of fluvastatin on prothrombotic and fibrinolytic factors in type 2 diabetes mellitus. Am J Cardiol 1999; 84: 934-937.

    Google Scholar 

  184. Wiesbauer F,Kaun C,Zorn G,Maurer G,Huber K,Wojta J. HMGCoA reductase inhibitors affect the fibrinolytic system of human vascular cells in vitro: A comparative study using different statins. Br J Pharmacol 2002; 135: 284-292.

    Google Scholar 

  185. Lau WC,Waskell LA,Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: A new drug-drug interaction. Circulation 2003; 107: 32-37.

    Google Scholar 

  186. Serebruany VL,Steinhubl SR,Hennekens CH. Are antiplatelet effects of clopidogrel inhibited by atorvastatin? A research question formulated but not yet adequately tested. Circulation 2003; 107: 1568-1569.

    Google Scholar 

  187. Yeo KR,Yeo WW. Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes. Br J Clin Pharmacol 2001; 51: 461-470.

    Google Scholar 

  188. Gruer PJ,Vega JM,Mercuri MF,Dobrinska MR,Tobert JA. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. Am J Cardiol 1999; 84: 811-815.

    Google Scholar 

  189. Kanathur N,Mathai MG,Byrd RP Jr,Fields CL,Roy TM. Simvastatin-diltiazem drug interaction resulting in rhabdomyolysis and hepatitis. Tenn Med 2001; 94: 339-341.

    Google Scholar 

  190. Peces R,Pobes A. Rhabdomyolysis associated with concurrent use of simvastatin and diltiazem. Nephron 2001; 89: 117-118.

    Google Scholar 

  191. Niemi M,Cascorbi I,Timm R, et al. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin Pharmacol Ther 2002; 72: 326-332.

    Google Scholar 

  192. Appel S,Rufenacht T,Kalafsky G, et al. Lack of interaction between fluvastatin and oral hypoglycemic agents in healthy subjects and in patients with non-insulin-dependent diabetes mellitus. Am J Cardiol 1995; 76: 29A-32A.

    Google Scholar 

  193. Lin JC,Ito MK. A drug interaction between troglitazone and simvastatin. Diabetes Care 1999; 22: 2104-2105.

    Google Scholar 

  194. Alsheikh-Ali AA,Abourjaily HM,Karas RH. Risk of adverse events with concomitant use of atorvastatin or simvastatin and glucose-lowering drugs (thiazolidinediones, metformin, sulfonylurea, insulin, and acarbose). Am J Cardiol 2002; 89: 1308-1310.

    Google Scholar 

  195. Sahi J,Black CB,Hamilton GA, et al. Comparative Effects of Thiazolidinediones on in Vitro P450 Enzyme Induction and Inhibition. Drug Metab Dispos 2003; 31: 439-446.

    Google Scholar 

  196. Gegick CG,Altheimer MD. Comparison of effects of thiazolidinediones on cardiovascular risk factors: Observations from a clinical practice. Endocr Pract 2001; 7: 162-169.

    Google Scholar 

  197. Khan MA,St Peter JV,Xue JL. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 2002; 25: 708-711.

    Google Scholar 

  198. Prueksaritanont T,Vega JM,Zhao J, et al. Interactions between simvastatin and troglitazone or pioglitazone in healthy subjects. J Clin Pharmacol 2001; 41: 573-581.

    Google Scholar 

  199. Attman P-O,Samuelsson O,Alaupovic P. Lipoprotein metabolism and renal failure. AmJ Kidney Dis 1993; 21: 573-592.

    Google Scholar 

  200. Maschio G,Oldizzi L,Rugio C, et al. Effect of dietary manipulation of the lipid abnormalities in patients with chronic renal failure. Kidney Int 1991; 31 (Suppl): S70-S72.

    Google Scholar 

  201. Samuelsson O,Aurell M,Knight-Gibson C, et al. Apolipoprotein-B-containing lipoproteins and the progression of renal insufficiency. Nephron 1993; 63: 279-285.

    Google Scholar 

  202. Sahadevan M,Kasiske BL. Hyperlipidemia in kidney disease: Causes and consequences. Curr Opin Nephrol Hypertens 2002; 11: 323-329.

    Google Scholar 

  203. Attman P-O,Alaupovic P,Sameulsson O. Lipoprotein abnormalities as a risk factor for progressive nondiabetic renal disease. Kidney Int 1999; 56(Suppl 71): S14-S17.

    Google Scholar 

  204. Oda H,Keane WR. Lipid abnormalities in end stage renal disease. Nephrol Dial Transplant 1998; 13(Suppl 1): 45-49.

    Google Scholar 

  205. Buemi M,Senatore M,Corica F, et al. Statins and progressive renal disease. Med Res Rev 2002; 22: 76-84.

    Google Scholar 

  206. Sica DA,Gehr TWB. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and rhabdomyolysis: Considerations in the renal failure patient. Curr Opin Nephrol Hypertens 2002; 11: 123-133.

    Google Scholar 

  207. Halstenson CE,Triscari J,DeVault A,Shapiro B,Keane W,Pan H. Single-dose pharmacokinetics of pravastatin and metabolites in patients with renal impairment. J Clin Pharmacol 1992; 32: 124-132.

    Google Scholar 

  208. Appel-Dingemanse S,Smith T,Merz M. Pharmacokinetics of fluvastatin in subjects with renal impairment and nephrotic syndrome. J Clin Pharmacol 2002; 42: 312-318.

    Google Scholar 

  209. Stern RH,Yang BB,Horton M,Moore S,Abel RB,Olson SC. Renal dysfunction does not alter the pharmacokinetics or LDL-cholesterol reduction of atorvastatin. J Clin Pharmacol 1997; 37: 816-819.

    Google Scholar 

  210. Scripture CD,Pieper JA. Clinical pharmacokinetics of fluvastatin. Clin Pharmacokinet 2001; 40: 263-281.

    Google Scholar 

  211. Lipitor® (atorvastatin) prescribing information. Pfizer Inc., April 2002

  212. Olbricht CJ,Wanner C,Thiery J,Basten A. Simvastatin in nephrotic syndrome. Simvastatin in Nephrotic Syndrome Study Group. Kidney Int Suppl 1999; 71: S113-S116.

    Google Scholar 

  213. Gheith OA,Sobh MA,Mohamed KE, et al. Impact of treatment of dyslipidemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome. Nephron 2002; 91: 612-619.

    Google Scholar 

  214. Spitalewitz S,Porush JG,Cattran D,Wright N. Treatment of hyperlipidemia in the nephrotic syndrome: The effects of pravastatin therapy. Am J Kidney Dis 1993; 22: 143-150.

    Google Scholar 

  215. Prata MM,Nogueira AC,Pinto JR, et al. Long-term effect of lovastatin on lipoprotein profile in patients with primary nephrotic syndrome. Clin Nephrol 1994; 41: 277-283.

    Google Scholar 

  216. Gascón A,Zabala S,Iglesias E. Acute cholestasis during long-term treatment with fluvastatin in a nephrotic patient. Nephrol Dial Transplant 1999; 14: 1038.

    Google Scholar 

  217. Seliger SL,Weiss NS,Gillen DL, et al. HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 2002; 61: 297-304.

    Google Scholar 

  218. Tonelli M,Moye L,Sacks FM,Kiberd B,Curhan G. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med 2003; 138: 98-104.

    Google Scholar 

  219. Lintott CJ,Scott RS,Bremer JM,Shand BI. Fluvastatin for dyslipoproteinemia, with or without concomitant chronic renal insufficiency. Am J Cardiol 1995; 76: 97A-101A.

    Google Scholar 

  220. Samuelsson O,Attman PO,Knight-Gibson C, et al. Fluvastatin improves lipid abnormalities in patients with moderate to advanced chronic renal insufficiency. Am J Kidney Dis 2002; 39: 67-75.

    Google Scholar 

  221. Nishikawa O,Mune M,Miyano M, et al. Effect of simvastatin on the lipid profile of hemodialysis patients. Kidney Int Suppl 1999; 71: S219-S221.

    Google Scholar 

  222. Saltissi D,Morgan C,Rigby RJ,Westhuyzen J. Safety and ef-ficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. Am J Kidney Dis 2002; 39: 283-290.

    Google Scholar 

  223. Tanaka M,Itoh K,Matsushita K, et al. Effects of fluvastatin on plasma lipid abnormalities in hemodialysis patients with chronic renal failure (Article in Japanese). Nippon Jinzo Gakkai Shi 2002; 44: 402-408.

    Google Scholar 

  224. Ichihara A,Hayashi M,Ryuzaki M, et al. Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus. Nephrol Dial Transplant 2002; 17: 1513-1517.

    Google Scholar 

  225. Wanner C,Horl WH,Luley CH,Wieland H. Effects of HMGCoA reductase inhibitors in hypercholesterolemic patients on hemodialysis. Kidney Int 1991; 39: 754-760.

    Google Scholar 

  226. Nishizawa Y,Shoji T,Emoto M, et al. Reduction of intermediate density lipoprotein by pravastatin in hemo and peritoneal dialysis patients. Clin Nephrol 1995; 43: 268-277.

    Google Scholar 

  227. Wanner C,Krane V,Ruf G,Marz W,Ritz E. Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. Die Deutsche Diabetes Dialyse Studie Investigators. Kidney Int Suppl 1999; 71: S222-S226.

    Google Scholar 

  228. Kasiske BL. Risk factors for accelerated atherosclerosis in renal transplant recipients. Am J Med 1988; 84: 985-992.

    Google Scholar 

  229. Bittar AE,Ratcliffe PJ,Richardson AJ, et al. The prevalence of hyperlipidemia in renal transplant recipients: Associations with immunosuppressive and antihypertensive therapy. Transplantation 1990; 50: 987-992.

    Google Scholar 

  230. Pirsch JD,D'Alessandro AM,Sollinger HW, et al. Hyperlipidemia and transplantation: Etiologic factors and therapy. J Am Soc Nephrol 1992; 2: S238-S242.

    Google Scholar 

  231. Kasiske BL,Umen AJ. Persistent hyperlipidemia in renal transplant patients. Medicine 1987; 66: 309-316.

    Google Scholar 

  232. Horl WH,Riegel W,Wanner C, et al. Endocrine and metabolic abnormalities following kidney transplantation. Klin Wochenschr 1989; 67: 907-918.

    Google Scholar 

  233. Bumgardner GL,Wilson GA,Tso PL, et al. Impact of serum lipids on long-term graft and patient survival after renal transplantation. Transplantation 1995; 60: 1418-1421.

    Google Scholar 

  234. Kobashigawa JA,Kasiske BL. Hyperlipidemia in solid organ tranpslantation. Transplantation 1997; 63: 331-338.

    Google Scholar 

  235. Vathsala A,Weinberg RB,Schoenberg L, et al. Lipid abnormalities in cyclosporine-prednisone-treated renal transplant recipients. Transplantation 1989; 48: 37-43.

    Google Scholar 

  236. Appel GA. Lipid abnormalities in renal disease. Kidney Int 1991; 39: 169-183.

    Google Scholar 

  237. Holdaas H,Jardine AG,Wheeler DC, et al. Effect of fluvastatin on acute renal allograft rejection: A randomized multicenter trial. Kidney Int 2001; 60: 1990-1997.

    Google Scholar 

  238. Fellström B. Impact and management of hyperlipidemia posttransplantation. Transplantation 2000; 70(Suppl 11): S51-S57.

    Google Scholar 

  239. Raine AEG. Hypertension and ischaemic heart disease in renal transplant recipients. Nephrol Dial Transplant 1995; 10(Suppl 1): 95-100.

    Google Scholar 

  240. Aakhus S,Dahl K,Wideröe T. Cardiovascular morbidity and mortality in renal transplant recipients. Results from a 5 year follow-up. Nephrol Dial Transplant 1999; 14: 648-654.

    Google Scholar 

  241. Isoniemi H,Nurminen M,Tikkanen ML, et al. Risk factors predicting chronic rejection of renal allografts. Transplantation 1994; 57: 68-72.

    Google Scholar 

  242. Dimeny E,Wahlberg J,Lethell H, et al. Hyperlipidaemia in renal transplantation: Risk factor for long-term graft outcome. Eur J Clin Invest 1995; 25: 574-583.

    Google Scholar 

  243. Ballantyne CM. Statins after cardiac transplantation: Which statin, what dose, and how low should we go? J Heart Lung Transplant 2000; 19: 115-117.

    Google Scholar 

  244. Wenke K,Meiser B,Thiery J, et al. Simvastatin initiated early after heart transplantation: 8-year prospective experience. Circulation 2003; 107: 93-97.

    Google Scholar 

  245. Kotanko P,Kirisits W,Skrabal F. Rhabdomyolysis and acute renal graft impairment in a patient treated with simvastatin, tacrolimus, and fusidic acid. Nephron 2002; 90: 234-235.

    Google Scholar 

  246. Regazzi MB,Iacona I,Campana C, et al. Altered disposition of pravastatin following concomitant drug therapy with cyclosporinAin transplant recipients. Transplant Proc 1993; 25: 2732-2734.

    Google Scholar 

  247. Asberg A,Hartmann A,Fjeldsa E, et al. Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients. Am J Transplant 2001; 1: 382-386.

    Google Scholar 

  248. Blaison G,Weber JC,Sachs D, et al. Rhabdomyolysis caused by simvastatin in a patient following heart transplantation and cyclosporine therapy. [article in French] Rev Med Intern 1992; 13: 61-63.

    Google Scholar 

  249. Maltz HC,Balog DL,Cheigh JS. Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine. Ann Pharmacother 1999; 33: 1176-1179.

    Google Scholar 

  250. Ghods AJ,Milanian I,Arghani H,Ghadiri G. The efficacy and safety of fluvastatin in hypercholsterolemia in renal transplant recipients. Transplant Proc 1995; 27: 2579-2580.

    Google Scholar 

  251. Holdaas H,Hartmann A,Strenstrom J, et al. Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine. Am J Cardiol 1995; 76: 102A-106A.

    Google Scholar 

  252. Austen JL,Shifrin FA,Bartucci MR, et al. Effects of fluvastatin on hyperlipidemia after renal transplantation: In-fluence of steroid therapy. Ann Pharmacother 1996; 30: 1386-1389.

    Google Scholar 

  253. Gomez G,Alvarez ML,Errasti P, et al. Fluvastatin in the treatment of hypercholesterolemia in renal transplantation. Transplant Proc 1999; 31: 2326-2327.

    Google Scholar 

  254. Jardine A,Holdaas H. Fluvastatin in combination with cyclosporin in renal transplant recipients: A review of clinical and safety experience. J Clin Pharm Ther 1999; 24: 397-408.

    Google Scholar 

  255. Malyszko JS,Malyszko J,Mysliwiec M. Serum lipids and hemostasis in kidney allograft recipients treated with fluvastatin (Lescol) for 3 months. Transplant Proc 2000; 32: 1344-1346.

    Google Scholar 

  256. Li PK,Mak TW,Wang AY, et al. Theinteraction of fluvastatin and cyclosporin A in renal transplant patients. Int J Clin Pharmacol Ther 1995; 33: 246-248.

    Google Scholar 

  257. Foldes K,Maklary E,Vargha P, et al. Effect of diet and fluvastatin treatment on the serum lipid profile of kidney transplant, diabetic recipients:A1-year follow up. Transplant Int 1998; 11(Suppl 1): S65-S68.

    Google Scholar 

  258. Holdaas H,Fellström B,Holme I, et al. Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol_R in Renal Transplantation) study design and baseline data. J Cardiovasc Risk 2001; 8: 63-71.

    Google Scholar 

  259. Holdaas H, Julian D. The use of statins after solid organ transplantation. Nephrol Dial Transplant 2002; 17:1538.

    Google Scholar 

  260. Katznelson S,Wilkinson AH,Kobashigawa JA. The effect of pravastatin on acute rejection after kidney transplantation-A pilot study. Transplantation 1996; 61: 1469-1474.

    Google Scholar 

  261. Wenke K,Meiser B,Thiery J, et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation: A four-year randomized trial. Circulation 1997; 96: 1398-1402.

    Google Scholar 

  262. Sahu K,Sharma R,Gupta A, et al. Effect of lovastatin, an HMG CoA reductase inhibitor, on acute renal allograft rejection. Clin Transplant 2001; 15: 173-175.

    Google Scholar 

  263. Kasiske BL,Heim-Duthoy KL,Singer GG,Watschinger B,Germain MJ,Bastani B. The effects of lipid-lowering agents on acute renal allograft rejection. Transplantation 2001; 72: 223-227.

    Google Scholar 

  264. Grunfeld C,Pang M,Doerrler W, et al. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunode-ficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992; 74: 1045-1052.

    Google Scholar 

  265. Dubé MP,Sprecher D,Henry WK, et al. Preliminary guidelines for the evaluation and management of dyslipidemia in HIV-infected adults receiving antiretroviral therapy: Recommendations of the Adult ACTG Cardiovascular Disease Focus Group. Clin Infect Dis 2000; 31: 1216-1224.

    Google Scholar 

  266. Lenhard JM,Croom DK,Weiel JE,Winegar DA. HIV protease inhibitors stimulate hepatic triglyceride synthesis. Arterioscler Thromb Vasc Biol 2000; 20: 2625-2629.

    Google Scholar 

  267. Segerer S,Bogner JR,Walli R, et al. Hyperlipidemia under treatment with proteinase inhibitors. Infection 1999; 27: 77-81.

    Google Scholar 

  268. Romeu J,Sirera G,Rego MJ, et al. Cumulative risk for developing hyperlipidemia in HIV-infected patients treated with protease inhibitors. In: Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Sept. 26-29, 1999

  269. Currier JS. Metabolic complications of antiretroviral therapy and HIV infection. HIV/AIDS: Annual Update 2001. Available from: http://www.medscape.com/viewarticle/ 418630.

  270. Martinez E,Conget I,Lozano L, et al. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 1999; 13: 805-810.

    Google Scholar 

  271. Rozenbaum W,Molina JM,Delfraissy JF, et al. Improvement of lipodystrophy in HIV-1 infected subjects switching from 2NRTI/PI to 2NRTI/abacavir (French substudy, CNA30017). 7th Conference on Retroviruses and Opportunistic Infections; Jan. 3-Feb. 2, 2000; San Francisco, California. Abstract 47.

  272. Bonnet E,Lepec R,Bluteau M, et al. Evoluation of lipodystrophy syndrome and lipidic profile in HIV patients after switching from protease inhibitors to efavirenz. 30 Jan.-2 Feb., 2000; San Francisco, California. Abstract 51.

  273. Kaul DR,Cinti SK,Carver PL, et al. HIV protease inhibitors: Advances in therapy and adverse reactions, including metabolic complications. Pharmacotherapy 1999; 19: 281-298.

    Google Scholar 

  274. Henry K,Melroe H,Huebesch J, et al. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities. Lancet 1998; 352: 1031-1032.

    Google Scholar 

  275. Murillas J,Martin T,Ramos A,Portero JL. Atorvastatin for protease inhibitor-related hyperlipidaemia. AIDS 1999; 13: 1424-1425.

    Google Scholar 

  276. van Heeswijk RP,Veldkamp A,Mulder JW, et al. Combination of protease inhibitors for the treatment of HIV-1-infected patients: A review of pharmacokinetics and clinical experience. Antivir Ther 2001; 6: 201-229.

    Google Scholar 

  277. Hsyu PH,Schultz-Smith MD,Lillibridge JH, et al. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrob Agents Chemother 2001; 45: 3445-3450.

    Google Scholar 

  278. Panel on Clinical Practices for the Treatment of HIV Infection Convened by the Department of Health and Human Services and the Henry J Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIVinfected adults and adolescents. Jan. 28, 2000. Available from: http://www.hivatis.org.

  279. Fichtenbaum CJ,Gerber JG,Rosenkranz SL, et al. Pharmacokinetic interactions between protease inhibitors and statins inHIVseronegative volunteers:ACTGStudy A5047. AIDS 2002; 16: 569-577.

    Google Scholar 

  280. Piliero PJ. Interaction between ritonavir and statins. Am J Med 2002; 112: 510-511.

    Google Scholar 

  281. Fichtenbaum C,Gerber J,Rosenkranz S, et al. Pharmacokinetic interactions between protease inhibitors and selected HMG-CoA reductase inhibitors. Presented at the 7th Conference on Retroviruses and Opportunistic Infections. Jan. 30-Feb. 2, 2000; San Francisco, California.

  282. Kuper JJ,D'Aprile M. Drug-drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. Clin Pharmacokinet 2000; 39: 203-214.

    Google Scholar 

  283. Michalets EL. Update: Clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998; 18: 84-112.

    Google Scholar 

  284. Bottorff M. Fire and forget?-Long-term considerations of coronary care. Atherosclerosis 1999; 147(Suppl 1): S23-S30.

    Google Scholar 

  285. Heerey A,Barry M,Ryan M,Kelly A. The potential for drug interactions with statin therapy in Ireland. Ir J Med Sci 2000; 169: 176-179.

    Google Scholar 

  286. American Heart Association and American College of Cardiology Advisory. ACC and AHA reassure patients about statins' effectiveness, safety. Physician's patients urged to discuss concerns, side effects and options for lowering cholesterol. News Release, 30 August 2001. Available from: http://www.americanheart.org/Whats News/AHA News Releases/30Aug3001100715 01.html

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacological Sciences, University of Milan, via Balzaretti 9, 20133, Milan, Italy

    Alberto Corsini

Authors
  1. Alberto Corsini
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Corsini, A. The Safety of HMG-CoA Reductase Inhibitors in Special Populations at High Cardiovascular Risk. Cardiovasc Drugs Ther 17, 265–285 (2003). https://doi.org/10.1023/A:1026132412074

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1026132412074

Search

Navigation